Chronic lymphocytic leukemia (CLL) develops when white blood cells called B-lymphocytes accumulate genetic changes that let them survive far longer than normal and multiply out of control. There is no single cause. Instead, CLL results from a combination of chromosomal damage, immune system signaling errors, and, in some cases, environmental exposures or inherited genetic traits. The median age at diagnosis is 69, and the disease is roughly twice as common in men as in women.
How Normal B-Cells Become Cancerous
B-lymphocytes are immune cells that normally produce antibodies to fight infection. In CLL, a subset of these cells acquires mutations that disrupt the built-in self-destruct mechanism (apoptosis) every healthy cell relies on to die when it’s damaged or no longer needed. Protected from that normal death signal, the abnormal B-cells keep circulating between the blood and lymph tissues, accumulating over months and years.
A key driver is the signaling that occurs through the receptor on the surface of each B-cell. In healthy immune function, this receptor recognizes foreign invaders. In CLL, the receptor responds instead to the body’s own proteins (self-antigens), creating a repeating cycle that stimulates the leukemia cells to survive and divide. The degree of that stimulation helps explain why some people have slow-growing CLL while others have an aggressive form.
Researchers now classify CLL into two biologically distinct diseases based on whether a specific gene region (called IGHV) has undergone mutation. Mutated IGHV CLL tends to grow slowly, with cells tipped toward a dormant, low-energy state. Unmutated IGHV CLL is more proliferative and typically follows a more aggressive course. In the unmutated form, one particular gene variant (IGHV1-69) dominates, suggesting that a specific type of immune trigger, called a superantigen, plays a role in launching the disease.
Chromosomal Abnormalities Behind CLL
Most CLL cells carry recognizable chromosomal damage. These aren’t inherited defects you’re born with. They’re acquired changes that develop in blood-forming cells over a lifetime. The four most common abnormalities, and their approximate frequency among CLL patients, are:
- Deletion of part of chromosome 13 (13q): Found in roughly 55% of cases. This is the most common change and is generally associated with slower disease progression.
- Extra copy of chromosome 12 (trisomy 12): Present in about 15% of cases. Associated with intermediate risk.
- Deletion on chromosome 11 (11q): Found in approximately 15% of cases. Linked to more aggressive disease and bulky lymph node involvement.
- Deletion on chromosome 17 (17p): Present in 5 to 8% of cases. This removes part of a critical tumor-suppressor gene and is associated with the most resistant, hardest-to-treat CLL.
A study published in PNAS found that an additional layer of genetic damage often goes undetected. About 34% of all CLL samples carry a tiny deletion affecting a pair of molecules (miR-15a/16-1) that normally act as brakes on cell growth. These microdeletions appear across every chromosomal subtype, not just the 13q group where they were first discovered. Around 40% of patients with trisomy 12, 17p deletion, or 11q deletion also carry this hidden loss, and higher rates of it correlate with more aggressive disease. This matters clinically because subclones with this deletion can gain a survival advantage over time, potentially driving progression or relapse after treatment.
Environmental and Chemical Exposures
CLL is one of the few blood cancers with a recognized link to herbicide exposure. The National Academy of Sciences concluded that there is sufficient evidence of an association between Agent Orange exposure and CLL. Based on that finding, the U.S. Department of Veterans Affairs recognized the connection in 2003 and expanded it in 2010 to cover all chronic B-cell leukemias. Veterans who were exposed to Agent Orange or similar herbicides during service do not have to prove a direct connection between their disease and their exposure to qualify for disability benefits.
Benzene, a chemical found in gasoline, industrial solvents, and cigarette smoke, is classified as carcinogenic to humans by the World Health Organization’s International Agency for Research on Cancer. Benzene is most strongly linked to acute myeloid leukemia, but IARC also notes associations with CLL and other blood cancers. The evidence for benzene and CLL specifically is not as strong as it is for AML, but the link has been observed across multiple studies.
Farming and agricultural work have also appeared as risk factors in epidemiological research, likely because of long-term pesticide exposure, though pinpointing a single chemical responsible has been difficult.
Family History and Inherited Risk
CLL has one of the strongest familial patterns of any blood cancer. Data from the Utah Cancer Registry suggest that 6 to 8% of CLL cases have a family connection. If you have a first-degree relative (parent, sibling, or child) with CLL, your risk is meaningfully higher than the general population’s.
One clue to the inherited component comes from a gene called POT1, which helps protect the ends of chromosomes. Families carrying a germline POT1 mutation tend to develop CLL without the mixed pattern of solid tumors seen in other cancer-predisposition syndromes. Beyond diagnosed CLL, up to 13 to 17% of unaffected first-degree relatives of CLL patients show a precursor condition called monoclonal B-cell lymphocytosis (MBL), where small numbers of abnormal B-cells circulate in the blood without meeting the threshold for leukemia.
Monoclonal B-Cell Lymphocytosis: The Precursor Stage
CLL doesn’t appear overnight. Nearly all cases are preceded by MBL, a condition in which abnormal B-cells are detectable in the blood but at levels below 5,000 per cubic millimeter, the diagnostic threshold for CLL. MBL is remarkably common in older adults and is often found incidentally on blood tests done for other reasons.
Most people with MBL will never develop leukemia. For those with higher-count MBL (the type typically identified in a clinical setting rather than a screening study), the rate of progression to CLL requiring treatment is estimated at about 1.4% per year. That means the vast majority of people with MBL can be monitored without intervention, though the condition does warrant periodic blood counts to catch any change early.
Who Gets CLL: Age, Sex, and Ethnicity
CLL is overwhelmingly a disease of older adults. It is rare before age 40, and the median diagnosis comes at 69. Men develop CLL at nearly twice the rate of women: 6.0 new cases per 100,000 men versus 3.5 per 100,000 women each year in the United States. The reasons for this sex difference are not fully understood, though hormonal and immune differences between sexes are suspected contributors.
Ethnicity plays a striking role. Non-Hispanic White men have the highest incidence at 7.4 per 100,000, while Non-Hispanic Asian/Pacific Islander men have the lowest at 1.8 per 100,000. The pattern holds among women: 4.3 per 100,000 for Non-Hispanic White women compared to 0.9 for Non-Hispanic Asian/Pacific Islander women. Hispanic and Black populations fall in between. These disparities persist even after accounting for differences in healthcare access and screening, pointing to underlying genetic variation across populations in susceptibility to the disease.
What Can Trigger CLL to Worsen
For many people, CLL remains stable for years or even decades. But the disease can accelerate when leukemia cells acquire additional mutations. The accumulation of new chromosomal abnormalities, particularly 17p deletions or mutations in a gene called NOTCH1, is associated with faster progression and treatment resistance.
In roughly 2 to 10% of CLL patients, the disease undergoes what’s called Richter transformation, converting into a fast-growing, aggressive lymphoma. Patients with NOTCH1 mutations or multiple chromosomal abnormalities in their leukemia cells face a higher risk of this transformation. Richter transformation changes the nature of the disease entirely and requires a different treatment approach from standard CLL management.